1-5 of 5
Rachael A. Vaubel
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Modeling the Acute Mucosal Toxicity of Fractionated Radiotherapy Combined with the ATM Inhibitor WSD0628

Darwin A. Garcia, Sneha Rathi, Margaret A. Connors, Michael Grams, Rachael A. Vaubel, Katrina K. Bakken, Lauren L. Ott, Brett L. Carlson, Zeng Hu, Paul A. Decker, Jeanette E. Eckel-Passow, Danielle M. Burgenske, Wei Zhong, Joshua D. Trzasko, Michael G. Herman, William F. Elmquist, Nicholas B. Remmes, Jann N. Sarkaria
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther OF1–OF11.
https://doi.org/10.1158/1535-7163.MCT-24-0664
Published: 09 December 2024
View article titled, Modeling the Acute Mucosal Toxicity of Fractionated Radiotherapy Combined with the ATM Inhibitor WSD0628
Open the PDF for Modeling the Acute Mucosal Toxicity of Fractionated Radiotherapy Combined with the ATM Inhibitor WSD0628 in another window
Includes: Supplementary data
Journal Articles

Delivery versus Potency in Treating Brain Tumors: BI-907828, a MDM2-p53 Antagonist with Limited BBB Penetration but Significant In Vivo Efficacy in Glioblastoma

Wenjuan Zhang, Rachael A. Vaubel, Ju-Hee Oh, Ann C. Mladek, Surabhi Talele, Wenqiu Zhang, Katie L. Waller, Danielle M. Burgenske, Jann N. Sarkaria, William F. Elmquist
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2024) 23 (1): 47–55.
https://doi.org/10.1158/1535-7163.MCT-23-0217
Published: 03 January 2024
View article titled, Delivery versus Potency in Treating Brain Tumors: BI-907828, a MDM2-p53 Antagonist with Limited BBB Penetration but Significant <em>In Vivo</em> Efficacy in Glioblastoma
Open the PDF for Delivery versus Potency in Treating Brain Tumors: BI-907828, a MDM2-p53 Antagonist with Limited BBB Penetration but Significant <em>In Vivo</em> Efficacy in Glioblastoma in another window
Includes: Supplementary data
Journal Articles

Abstract A148: The radiosensitizing effects of the novel brain penetrant and potent ATM inhibitor WSD0628 in glioblastoma and melanoma patient derived xenografts

Zhiyi Xue, Ann C. Mladek, Sneha Rathi, Danielle M. Burgenske, Shiv K. Gupta, Brett L. Carlson, Zeng Hu, Lauren L Ott, Katrina K. Bakken, Rachael A. Vaubel, William F Elmquist, Wei Zhong, Jann N Sarkaria
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): A148.
https://doi.org/10.1158/1535-7163.TARG-23-A148
Published: 01 December 2023
View article titled, Abstract A148: The radiosensitizing effects of the novel brain penetrant and potent ATM inhibitor WSD0628 in glioblastoma and melanoma patient derived xenografts
Journal Articles

Abstract C096: Modeling the clinical paradigm of lisavanbulin (BAL101553) deployment in patient-derived xenografts (PDX) of glioblastoma (GBM)

Danielle M Burgenske, Ann C Mladek, Jenny L Pokorny, Heidi A Lane, Felix Bachmann, Rachael A Vaubel, Mark A Schroeder, Katrina K Bakken, Lihong He, Zeng Hu, Brett L Carlson, Surabhi Talele, Gautham Gampa, Matthew L Kosel, Paul A Decker, Jeanette E Eckel-Passow, William F Elmquist, Jann Sarkaria
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): C096.
https://doi.org/10.1158/1535-7163.TARG-19-C096
Published: 01 December 2019
View article titled, Abstract C096: Modeling the clinical paradigm of lisavanbulin (BAL101553) deployment in patient-derived xenografts (PDX) of glioblastoma (GBM)
Journal Articles

Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood–Brain Barrier

Minjee Kim, Daniel J. Ma, David Calligaris, Shuangling Zhang, Ryan W. Feathers, Rachael A. Vaubel, Isabelle Meaux, Ann C. Mladek, Karen E. Parrish, Fang Jin, Cedric Barriere, Laurent Debussche, James Watters, Shulan Tian, Paul A Decker, Jeanette E. Eckel-Passow, Gaspar J. Kitange, Aaron J. Johnson, Ian F. Parney, Panos Z. Anastasiadis, Nathalie Y.R. Agar, William F. Elmquist, Jann N. Sarkaria
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (9): 1893–1901.
https://doi.org/10.1158/1535-7163.MCT-17-0600
Published: 04 September 2018
View article titled, Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood–Brain Barrier
Open the PDF for Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood–Brain Barrier in another window
Includes: Supplementary data